This report from Life Science Intelligence provides the latest market data for the Global Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market. Information covered by this report includes:
The global market for transcatheter aortic valve replacement/implantation is expected to reach an estimated $3.9 billion in 2020 and is projected to increase at a CAGR (2020-2024) of 18.7%. Forecasts for this report cover the markets for transcatheter aortic valve repair and replacement devices.
This report covers the impact of COVID-19 on heart valve replacement procedures, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors, such as Abbott, Boston Scientific, Medtronic, Edwards Lifesciences, and others. The report provides insights into trends, drivers, and limiters of the transcatheter aortic heart valves market, as well as highlights potential opportunities.
The transcatheter aortic heart valve market has seen exponential growth since the first device was launched in 2011 by Edwards Lifesciences. The expansion in indications in recent years, as well as the improved patient outcomes compared to the outcomes from other surgical aortic valve replacement devices, have led to an increase in the number of procedures. Favorable reimbursement for the procedure in the US and Europe has also led to faster adoption of the minimally-invasive approach.
The transcatheter aortic valve market is dominated by Edwards Lifesciences and Medtronic; with Boston Scientific recently gaining a small share in the USA and Europe. The high-growth segment has attracted many small companies which have made technological advancement to the device and gained regulatory approvals in Europe. Smaller players in this market include Colibri Heart Valve, JenaValve, Braile Biomedica, Thubrikar Aortic Valve, Blue Sail, Heart Leaflet Technologies, Venus Medtech, and Meril Life Sciences
The transcatheter aortic valve replacement market was impacted by the COVID-19 pandemic. Due to the non-invasive nature of the procedure, a minor procedure volume decline of approximately 2% was estimated to have occurred in 2020. The negative impact of COVID-19 on this market is fairly minimal when compared with other cardiac surgical procedures, which are estimated to have declined by approximately 20% to 25%.